Drugs / PRX-08066
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00677872 | May → Dec 2008 | chronic obstructive pulmonary disease, pulmonary hypertension | Epix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00345774 | Jun 2006 → Jun 2007 | chronic obstructive pulmonary disease, pulmonary hypertension | Epix Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRX-08066 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00345774 ↗ |
| Action | Inhibit | “Serotonin 2b (5-HT2b) receptor antagonist” CHEMBL513994 ↗ |
| Modality | Small molecule | — CHEMBL513994 ↗ |
| Target | HTR2B | “Serotonin 2b (5-HT2b) receptor antagonist” CHEMBL513994 ↗ |